Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses (mPRINT P50)

使用药物微生物组学和代谢组学分析优化母亲及其母乳喂养婴儿的抗生素 (mPRINT P50)

基本信息

项目摘要

PROJECT SUMMARY for MPRINT CET ADMINISTRATIVE CORE The primary goal of the UCSD MPRINT CET is to serve as a national resource for knowledge and expertise in maternal and pediatric pharmacology. The Multi-PI leadership of the UCSD MPRINT CET, who will lead three Research Projects and two Support Cores (Milk Analytics and Pharmacometrics) excels in research fields of maternal and infant health, human milk, antibiotic therapeutics, pharmacometrics, metabolomics and microbiome. In order to successfully execute the goals of this program, we have formulated an Administrative Core that will facilitate the research activities and provide timely and responsible oversight of the UCSD MPRINT CET. The Specific Aims of the Administrative Core are: Aim 1: Provide leadership and oversight for the UCSD MPRINT CET to maximize effective execution of the research program and achieve all deliverables and milestones. The Administrative Core leadership (Drs. Tremoulet and Chambers) and program manager (Kristin Woods) have exceptional track-records in administration of multisite networks and will coordinate communication and overall cohesiveness among the various elements of the UCSD MPRINT CET and MPRINT Hub. The Administrative Core will oversee the preparation of annual reports and publications, as well as handle ongoing critical evaluation and outcomes assessment to achieve continual improvement of the MPRINT CET effectiveness. In so doing the Administrative Core will optimize evaluation, reprioritization and adjustment of activities, timelines and milestones. This Core will provide continuous and accurate financial management by tracking the financial status of the UCSD MPRINT CET Projects, Cores, and Support Pool. Aim 2: Facilitate the interactions of the UCSD MPRINT CET that will maximize the contributions to the MPRINT Hub The Administrative Core leadership will identify emerging needs across the UCSD MPRINT CET to choose Support Pool projects that will enhance the MPRINT Hub's role as a national resource in pediatric and maternal clinical pharmacology. The Administrative Core will lead the effort to select the most meritorious and impactful Support Pool projects. This Core will also be responsible for all communication with the MPRINT's Knowledge and Research Coordination Center (KRCC) and support outreach and dissemination of new knowledge by coordinating with the MPRINT KRCC's Outreach, Dissemination, and Training Core. Finally, the Administrative Core will provide an integrated educational and practical mentored research training experience in maternal and pediatric clinical pharmacology for health sciences professionals interested in becoming leaders in the field. In achieving these aims, the Administrative Core will achieve its mission of fostering communication and collaboration across the Research Projects and Cores at UCSD, as well as coordinate closely with the MPRINT KRCC and the entire MPRINT Hub.
MPRINT CET行政核心的项目摘要 UCSD Mprint CET的主要目标是作为知识和专业知识的国家资源 孕产妇和小儿药理学。 UCSD Mprint CET的多P-PI领导,他将领导三个 研究项目和两个支持核心(牛奶分析和药物计量学)在研究领域的研究领域 孕产妇和婴儿健康,人乳,抗生素疗法,药物测量学,代谢组学和 微生物组。为了成功执行该计划的目标,我们已经制定了管理 将促进研究活动并及时,负责任的UCSD Mprint的核心 CET。行政核心的具体目的是:目标1:为 UCSD Mprint CET最大程度地实现了研究计划的有效执行并实现所有可交付成果 和里程碑。行政核心领导(Tremoulet和Chambers博士)和计划经理 (克里斯汀·伍兹(Kristin Woods))在管理多站点网络中具有出色的轨道记录,并将协调 UCSD MPRINT CET和MPRINT的各个元素之间的沟通和整体凝聚力 中心。行政核心将监督年度报告和出版物的准备,并处理 正在进行的批判性评估和结果评估,以持续改进MPRINT CET 效力。这样做的行政核心将优化评估,重新定位和调整 活动,时间表和里程碑。该核心将通过 跟踪UCSD MPRINT CET项目,核心和支持池的财务状况。目标2:促进 UCSD MPRINT CET的相互作用将最大化对Mprint Hub的贡献 行政核心领导将确定UCSD Mprint CET的新兴需求,以选择支持 泳池项目将增强MPRINT枢纽作为儿科和孕产妇临床中国家资源的作用 药理。行政核心将努力选择最有利和有影响力的支持 池项目。该核心还将负责与mprint知识的所有沟通 研究协调中心(KRCC),并支持推广和传播新知识 与Mprint KRCC的外展,传播和训练核心协调。最后,行政管理 核心将提供综合的教育和实践指导的研究培训经验 健康科学专业人员的儿科临床药理学有兴趣成为该领域的领导者。在 实现这些目标,行政核心将实现其促进沟通和 在UCSD的研究项目和核心之间进行协作,并与Mprint紧密协调 KRCC和整个Mprint中心。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ADRIANA H TREMOULET其他文献

ADRIANA H TREMOULET的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ADRIANA H TREMOULET', 18)}}的其他基金

Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses (mPRINT P50)
使用药物微生物组学和代谢组学分析优化母亲及其母乳喂养婴儿的抗生素 (mPRINT P50)
  • 批准号:
    10309712
  • 财政年份:
    2021
  • 资助金额:
    $ 19.27万
  • 项目类别:
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses (mPRINT P50)
使用药物微生物组学和代谢组学分析优化母亲及其母乳喂养婴儿的抗生素 (mPRINT P50)
  • 批准号:
    10681302
  • 财政年份:
    2021
  • 资助金额:
    $ 19.27万
  • 项目类别:
Phase I and IIa trial of atorvastatin in children with acute Kawasaki disease
阿托伐他汀治疗急性川崎病儿童的 I 期和 IIa 期试验
  • 批准号:
    9096853
  • 财政年份:
    2014
  • 资助金额:
    $ 19.27万
  • 项目类别:
Phase I and IIa trial of atorvastatin in children with acute Kawasaki disease
阿托伐他汀治疗急性川崎病儿童的 I 期和 IIa 期试验
  • 批准号:
    9216033
  • 财政年份:
    2014
  • 资助金额:
    $ 19.27万
  • 项目类别:
Pharmacologic Determinants for Optimized Therapy in HIV-Infected Children
HIV 感染儿童优化治疗的药理学决定因素
  • 批准号:
    8123189
  • 财政年份:
    2007
  • 资助金额:
    $ 19.27万
  • 项目类别:
Pharmacologic Determinants for Optimized Therapy in HIV-Infected Children
HIV 感染儿童优化治疗的药理学决定因素
  • 批准号:
    7490096
  • 财政年份:
    2007
  • 资助金额:
    $ 19.27万
  • 项目类别:
Pharmacologic Determinants for Optimized Therapy in HIV-Infected Children
HIV 感染儿童优化治疗的药理学决定因素
  • 批准号:
    7673722
  • 财政年份:
    2007
  • 资助金额:
    $ 19.27万
  • 项目类别:
Pharmacologic Determinants for Optimized Therapy in HIV-Infected Children
HIV 感染儿童优化治疗的药理学决定因素
  • 批准号:
    7908694
  • 财政年份:
    2007
  • 资助金额:
    $ 19.27万
  • 项目类别:
Pharmacologic Determinants for Optimized Therapy in HIV-Infected Children
HIV 感染儿童优化治疗的药理学决定因素
  • 批准号:
    7338088
  • 财政年份:
    2007
  • 资助金额:
    $ 19.27万
  • 项目类别:
Pediatric and Developmental Pharmacology for Inflammatory and Infectious Diseases
炎症和传染病的儿科和发育药理学
  • 批准号:
    9355662
  • 财政年份:
  • 资助金额:
    $ 19.27万
  • 项目类别:

相似海外基金

The role of Chlamydia trachomatis specific HLA-E restricted CD8 T cell responses in clearance of infection
沙眼衣原体特异性 HLA-E 限制性 CD8 T 细胞反应在感染清除中的作用
  • 批准号:
    10646837
  • 财政年份:
    2023
  • 资助金额:
    $ 19.27万
  • 项目类别:
Molecular basis of immunity to tick-borne rickettsioses
蜱传立克次体病免疫的分子基础
  • 批准号:
    10673274
  • 财政年份:
    2021
  • 资助金额:
    $ 19.27万
  • 项目类别:
Molecular basis of immunity to tick-borne rickettsioses
蜱传立克次体病免疫的分子基础
  • 批准号:
    10475572
  • 财政年份:
    2021
  • 资助金额:
    $ 19.27万
  • 项目类别:
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses (mPRINT P50)
使用药物微生物组学和代谢组学分析优化母亲及其母乳喂养婴儿的抗生素 (mPRINT P50)
  • 批准号:
    10309712
  • 财政年份:
    2021
  • 资助金额:
    $ 19.27万
  • 项目类别:
Molecular basis of immunity to tick-borne rickettsioses
蜱传立克次体病免疫的分子基础
  • 批准号:
    9989476
  • 财政年份:
    2021
  • 资助金额:
    $ 19.27万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了